HomeCompareMAQCW vs ABBV

MAQCW vs ABBV: Dividend Comparison 2026

MAQCW yields 18181.82% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAQCW wins by $20382968138483965952.00M in total portfolio value
10 years
MAQCW
MAQCW
● Live price
18181.82%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20382968138483965952.00M
Annual income
$20,164,798,479,641,134,000,000,000.00
Full MAQCW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MAQCW vs ABBV

📍 MAQCW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMAQCWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MAQCW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MAQCW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MAQCW
Annual income on $10K today (after 15% tax)
$1,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$17,140,078,707,694,964,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MAQCW beats the other by $17,140,078,707,694,964,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MAQCW + ABBV for your $10,000?

MAQCW: 50%ABBV: 50%
100% ABBV50/50100% MAQCW
Portfolio after 10yr
$10191484069241982976.00M
Annual income
$10,082,399,239,820,567,000,000,000.00/yr
Blended yield
98.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MAQCW
No analyst data
Altman Z
-7.3
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MAQCW buys
0
ABBV buys
0
No recent congressional trades found for MAQCW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMAQCWABBV
Forward yield18181.82%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$20382968138483965952.00M$102.3K
Annual income after 10y$20,164,798,479,641,134,000,000,000.00$24,771.77
Total dividends collected$20368560651224936448.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MAQCW vs ABBV ($10,000, DRIP)

YearMAQCW PortfolioMAQCW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,828,882$1,818,181.82$11,550$430.00+$1.82MMAQCW
2$312,726,966$310,770,062.56$13,472$627.96+$312.71MMAQCW
3$49,997,862,140$49,663,244,286.24$15,906$926.08+$49997.85MMAQCW
4$7,474,070,205,933$7,420,572,493,443.65$19,071$1,382.55+$7474070.19MMAQCW
5$1,044,712,232,322,833$1,036,714,977,202,484.10$23,302$2,095.81+$1044712232.30MMAQCW
6$136,547,911,758,351,100$135,430,069,669,765,680.00$29,150$3,237.93+$136547911758.32MMAQCW
7$16,689,313,388,956,088,000$16,543,207,123,374,653,000.00$37,536$5,121.41+$16689313388956.05MMAQCW
8$1,907,542,220,817,720,100,000$1,889,684,655,491,537,200,000.00$50,079$8,338.38+$1907542220817720.25MMAQCW
9$203,896,877,423,206,970,000,000$201,855,807,246,932,000,000,000.00$69,753$14,065.80+$203896877423206976.00MMAQCW
10$20,382,968,138,483,967,000,000,000$20,164,798,479,641,134,000,000,000.00$102,337$24,771.77+$20382968138483965952.00MMAQCW

MAQCW vs ABBV: Complete Analysis 2026

MAQCWStock

Maquia Capital Acquisition Corporation does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus its search on technology-focused middle market and emerging growth companies in North America. The company was incorporated in 2020 and is based in Miami, Florida.

Full MAQCW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MAQCW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MAQCW vs SCHDMAQCW vs JEPIMAQCW vs OMAQCW vs KOMAQCW vs MAINMAQCW vs JNJMAQCW vs MRKMAQCW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.